Correlation Between Akums Drugs and 63 Moons

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Akums Drugs and 63 Moons at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akums Drugs and 63 Moons into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Akums Drugs and and 63 moons technologies, you can compare the effects of market volatilities on Akums Drugs and 63 Moons and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akums Drugs with a short position of 63 Moons. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akums Drugs and 63 Moons.

Diversification Opportunities for Akums Drugs and 63 Moons

Akums63MOONSDiversified AwayAkums63MOONSDiversified Away100%
0.68
  Correlation Coefficient

Poor diversification

The 3 months correlation between Akums and 63MOONS is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Akums Drugs and and 63 moons technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on 63 moons technologies and Akums Drugs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akums Drugs and are associated (or correlated) with 63 Moons. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of 63 moons technologies has no effect on the direction of Akums Drugs i.e., Akums Drugs and 63 Moons go up and down completely randomly.

Pair Corralation between Akums Drugs and 63 Moons

Assuming the 90 days trading horizon Akums Drugs and is expected to under-perform the 63 Moons. But the stock apears to be less risky and, when comparing its historical volatility, Akums Drugs and is 1.05 times less risky than 63 Moons. The stock trades about -0.07 of its potential returns per unit of risk. The 63 moons technologies is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  43,665  in 63 moons technologies on December 12, 2024 and sell it today you would earn a total of  27,735  from holding 63 moons technologies or generate 63.52% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy53.0%
ValuesDaily Returns

Akums Drugs and  vs.  63 moons technologies

 Performance 
JavaScript chart by amCharts 3.21.15Dec2025Feb -20-10010203040
JavaScript chart by amCharts 3.21.15AKUMS 63MOONS
       Timeline  
Akums Drugs 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Akums Drugs and has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.
JavaScript chart by amCharts 3.21.15JanFebMarFebMar450500550600650
63 moons technologies 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days 63 moons technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
JavaScript chart by amCharts 3.21.15JanFebMarFebMar6007008009001,000

Akums Drugs and 63 Moons Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-4.83-3.62-2.41-1.190.01.082.183.274.37 0.0250.0300.0350.0400.045
JavaScript chart by amCharts 3.21.15AKUMS 63MOONS
       Returns  

Pair Trading with Akums Drugs and 63 Moons

The main advantage of trading using opposite Akums Drugs and 63 Moons positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akums Drugs position performs unexpectedly, 63 Moons can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 63 Moons will offset losses from the drop in 63 Moons' long position.
The idea behind Akums Drugs and and 63 moons technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance